AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 101 min read$TWST

Cho Dennis sold $51K of TWST

Cho Dennis (See Remarks) sold 412 shares of Twist Bioscience Corp (TWST) at $122.62 on 2026-09-08.

Original reporting
SEC EDGAR · Cho Dennis
Published Sep 10, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
high confidence
Mentioned
$TWST
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

Small insider sale, unlikely to move price but worth noting for monitoring.

02

Market read

Minor insider sale; limited trading relevance.

03

What to watch

Insider holds 73,651 shares post‑sale, indicating continued confidence.

Relevance 3/10Novelty 4/10Timing: transaction dated 2026-09-08, filed 2026-09-10

Background

Form 4 filings disclose insider transactions; traders monitor for signals.

Company-level read

Ticker impact

$TWSTNeutralHigh confidence
Context

Officer Cho Dennis sold 412 shares of Twist Bioscience for $50.5K via a Form 4 filing.

Expected impact

Minimal short-term price pressure; likely no material move.

Evidence & confidence

Form 4 is primary source; sale amount is small relative to market cap, so impact limited.

Market effects

Sector

None; biotech sector unchanged.

Regional

None; US market only minor effect.

Global

Low

Counterpoint

What could challenge this read

Sale could be routine liquidity need, not a bearish signal.

Key entities

  • Company
    Twist Bioscience Corp

    Biotech firm developing DNA synthesis platforms.

  • Officer
    Cho Dennis

    Company officer who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TWST insider trading history →

Related articles

OCT 5
$TWSTHigh

Twist Bioscience TWST Stock Jumps On AI Drug Discovery Deals

Twist Bioscience (TWST) stock rose 10.19% after announcing AI drug discovery deals with Eli Lilly's TuneLab. The company reported $118.4M in quarterly revenue, a $35.1M net loss, and positive operating cash flow of $1.1M. Analysts have raised price targets, with Guggenheim setting it at $212. TWST is seen as a key player in AI-driven biotech.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Bullish Target Hike

Twist Bioscience (TWST) stock rose 16.21% after announcing a partnership with Eli Lilly's AI drug discovery platform, TuneLab. The company reported Q3 revenue of $118.4M, with a gross margin of 52% but a net loss of $35.1M. Leerink raised its price target to $160, citing the AI-driven opportunity. TWST is trading at a high valuation with a price-to-sales ratio over 25.

timothysykes.com3 min
SEP 24
$TWSTMed

Twist Bioscience Stock Jumps As AI Deals Fuel Bullish Target Hike

Twist Bioscience (TWST) stock rose 8.35% on September 24, 2026, driven by its AI partnership with Eli Lilly's TuneLab platform. The company's stock has seen significant gains recently, trading at $171.74 from $139 over a few weeks. TWST reported quarterly revenue of $118.38M, with a net loss of $35.05M. Leerink raised its price target to $160, citing AI drug discovery opportunities.

timothysykes.com3 min